An observational study in Syncope and Collapse, sponsored by Istituto Auxologico Italiano. Not yet recruiting. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Istituto Auxologico Italiano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the present study is to evaluate clinical practice in the diagnosis of severe unexplained syncope among European Syncope Units adhering to the standards set forth by the ESC guidelines.
The Diamond study is an investigator-initiated, prospective, international, multicenter study, coordinated by the non-profit organization Gruppo Italiano Studio Sincope (GIMSI), conducted within European Syncope Units that fulfill the personnel and equipment criteria recommended by the European Heart Rhythm Association (EHRA) and the (GIMSI) (https://www.gimsi.it/modello-organizzativo/).
Eligibility of each center is certified by the head of the syncope unit, who completes a questionnaire confirming compliance with the required standards. Web-based Clinical Report Form (CRF). To allow uniform clinical data collection from participating centres, a web-based CRF, was designed Study workflow. Following documented patient consent, clinical personnel at the site -trained in the use of the web-app- will access the digital tool to enter the patient's I/E criteria assessment, personal information and medical history. From that point forward, data will be entered into the web-app on an ongoing basis, in accordance with the site's routine clinical practice, until the patient reaches a defined exit point (such as diagnosis of cardiac syncope, diagnosis of autonomic syncope, no syncope, no diagnosis), or drop-out (e.g., patient death, patient unable to comply with diagnostic pathway, etc.).
202 studies on the registry are indexed under Syncope; 37 are open to participants now.
This study's planned enrollment of 300 is above the median of 250 across 85 observational studies indexed under Syncope.
Browse Syncope studies →Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients referred to the Syncope Unit for severe unexplained syncope
Inclusion Criteria: Outpatients aged ≥16 years referred to the Syncope Unit due to severe, unexplained syncope and/or unexplained fall requiring comprehensive evaluation to identify the most appropriate mechanism-specific therapy.
Exclusion Criteria: Non-severe syncope Definitions.
Severe syncope is defined by the presence of one or more among the following:
Substantial impact on patient's quality of life (QoL)
High risk of outcomes
Non-severe syncope is defined by the presence of one or more among the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Syncope Unit
Diagnostic Test: Standardised guideline-based diagnostic flow-chart
At the initial evaluation, it is essential to exclude non-syncopal causes of transient loss of consciousness (TLOC) - such as epilepsy, psychogenic pseudosyncope, and other conditions of apparent loss of consciousness that may be incorrectly diagnosed as syncope. Once non-syncopal causes have been excluded and the loss of consciousness is determined to be syncopal in nature, the primary objective of the diagnostic work-up is to identify cases of cardiac syncope. Cardiac syncope is characterized by loss of consciousness due to a primary cardiac disorder, such as arrhythmias or structural heart disease, and requires prompt recognition and appropriate treatment due to its association with higher morbidity and mortality. When both cardiac syncope and non-syncopal causes of TLOC are reasonably ruled out, the diagnosis of autonomic syncope becomes likely. Autonomic syncope encompasses both reflex (neurally mediated) syncope and orthostatic hypotension and represents the most frequent cause
Rate of final diagnoses 2) Type of final diagnoses 3) Number of tests utilized to reach them.
Time frame: through study completion, an average of 1 year
Number of participants with adherence of the clinical practices to a theoretical diagnostic pathway
Time frame: through study completion, an average of 1 year
Assessment of number and costs of resource utilization associated to the clinical practices
Time frame: through study completion, an average of 1 year
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 44 observational studies under Syncope, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 13. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →